Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Novel Medications for Opiate Detoxification - 4

This study has been completed.
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Information provided by (Responsible Party):
Yale University Identifier:
First received: September 20, 1999
Last updated: July 24, 2013
Last verified: December 2002
The purpose of this study is to evaluate novel medications for opiate detoxification.

Condition Intervention Phase
Opioid-Related Disorders
Substance-Related Disorders
Drug: Clonidine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Novel Medications for Opiate Detoxification

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Withdrawal severity

Estimated Enrollment: 0
Study Start Date: September 1994
Study Completion Date: August 1999
Primary Completion Date: August 1999 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000279

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
  More Information

AM J Drug & Alc. Abuse 21(4): 453-467, 1995; Neuropsychopharm 13(4): 323-333, 1995; Neuropsychopharm 14(3): 187-193, 1996; J Pharma & Experimental Therapeutics 276(3): 1128-1135, 1996.

Responsible Party: Yale University Identifier: NCT00000279     History of Changes
Other Study ID Numbers: NIDA-09250-4  P50DA009250  P50-09250-4 
Study First Received: September 20, 1999
Last Updated: July 24, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antihypertensive Agents
Autonomic Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on October 26, 2016